Hospital
Honorhealth
Honorhealth was paid $7.97M by Medicaid between Sep 2020 and Dec 2024, across 149 billing codes. Its largest line is 99285, emergency room visit (most serious) — 31% of everything it billed.
33Billing provider infoHONORHEALTH
PHOENIX, AZ 85085
PHOENIX, AZ 85085
33aNPI1265063010assigned 01/30/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.97M
24GClaims256,701
24DCodes billed149
24AFirst – last monthSep 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#46 of 78
Median peer was paid$12.21M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 8,200 | $250K | |
| 2021 | 54,226 | $1.54M | |
| 2022 | 67,337 | $2.13M | |
| 2023 | 72,989 | $2.19M | |
| 2024incomplete | 53,949 | $1.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 31% | 6,431 | 5,777 | $2.45M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 7,524 | 7,028 | $1.46M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 7,738 | 7,113 | $1.11M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10% | 3,248 | 2,988 | $809K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.2% | 3,755 | 3,503 | $413K |
| 72125 | Computed tomography, cervical spine; without contrast material | 4.3% | 723 | 686 | $346K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.6% | 1,302 | 1,217 | $285K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.0% | 6,772 | 5,365 | $242K |
| G0378 | Hospital observation service, per hour | 2.5% | 4,429 | 1,892 | $200K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 2,092 | 1,946 | $189K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 1,729 | 554 | $131K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,060 | 968 | $65K |
137 more codes
| 70498 | <1% | 96 | $60K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,507 | $48K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 645 | $40K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,220 | $32K |
| 59025 | Fetal non-stress test | <1% | 381 | $30K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 414 | $8K |
| 76801 | <1% | 42 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 135 | $6K |
| 70496 | <1% | 85 | $6K | |
| 96376 | <1% | 3,300 | $5K | |
| 97161 | <1% | 596 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,652 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,906 | $3K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,558 | $3K |
| 80053 | Comprehensive metabolic panel | <1% | 12,053 | $2K |
| 93976 | <1% | 37 | $1K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 72 | $1K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,786 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,183 | $1K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,984 | $995.60 |
| 71045 | Radiologic examination, chest; single view | <1% | 5,378 | $947.93 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 157 | $894.93 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,292 | $861.01 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,782 | $699.05 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 765 | $662.21 |
| 73630 | <1% | 293 | $634.36 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,759 | $561.80 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $471.16 |
| 93971 | <1% | 370 | $436.78 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,210 | $401.33 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,466 | $379.13 |
| 81025 | <1% | 2,163 | $364.43 | |
| 83690 | <1% | 5,255 | $317.52 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 940 | $305.25 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 324 | $270.35 |
| 81001 | <1% | 9,600 | $249.66 | |
| 84484 | <1% | 5,946 | $236.17 | |
| 83880 | <1% | 1,553 | $230.32 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 446 | $219.04 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 129 | $215.40 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 446 | $214.26 |
| 73130 | <1% | 194 | $181.94 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,276 | $176.10 |
| 80306 | <1% | 1,801 | $172.35 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,829 | $148.77 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,793 | $148.35 |
| 85379 | <1% | 1,913 | $138.80 | |
| 83735 | <1% | 3,971 | $121.15 | |
| 97165 | <1% | 14 | $113.49 | |
| 84703 | <1% | 3,647 | $113.01 | |
| 87040 | <1% | 1,796 | $109.62 | |
| 84702 | <1% | 658 | $107.21 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,527 | $105.97 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,115 | $103.75 |
| 82248 | <1% | 3,422 | $101.59 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,682 | $95.34 |
| 85027 | <1% | 3,966 | $80.99 | |
| 73562 | <1% | 277 | $80.44 | |
| 85610 | <1% | 3,881 | $69.32 | |
| 86850 | <1% | 358 | $58.94 | |
| 73110 | <1% | 98 | $58.46 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 113 | $46.07 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,107 | $45.51 |
| 90715 | <1% | 142 | $43.21 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,783 | $43.16 |
| 80320 | <1% | 1,274 | $37.43 | |
| 73030 | <1% | 141 | $35.68 | |
| 87077 | <1% | 1,028 | $33.85 | |
| 87186 | <1% | 740 | $31.15 | |
| 83605 | <1% | 1,788 | $31.14 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,334 | $30.87 |
| 85730 | <1% | 2,154 | $29.94 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,213 | $27.76 |
| 82962 | <1% | 4,006 | $27.06 | |
| 94760 | <1% | 2,453 | $24.06 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 158 | $20.59 |
| 82550 | <1% | 748 | $20.40 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 894 | $18.38 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 74 | $15.48 |
| 85652 | <1% | 500 | $14.03 | |
| 87660 | <1% | 122 | $13.28 | |
| 87510 | <1% | 122 | $13.28 | |
| 87480 | <1% | 122 | $13.28 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,610 | $11.28 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,278 | $8.74 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,177 | $6.48 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 647 | $6.39 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,476 | $6.17 |
| 87205 | <1% | 234 | $5.48 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,419 | $5.01 |
| 82947 | <1% | 12 | $2.64 | |
| 86901 | <1% | 673 | $1.97 | |
| 86900 | <1% | 604 | $1.90 | |
| J3490 | Unclassified drugs | <1% | 35 | $0.95 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 220 | $0.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 34 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 964 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 152 | $0.00 |
| 84100 | 0% | 392 | $0.00 | |
| 96367 | 0% | 185 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 519 | $0.00 |
| 97116 | 0% | 103 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 351 | $0.00 |
| 85014 | 0% | 219 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 112 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 144 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 77 | $0.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 60 | $0.00 |
| 85007 | 0% | 100 | $0.00 | |
| 93970 | 0% | 29 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 44 | $0.00 |
| 73610 | 0% | 128 | $0.00 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 0% | 12 | $0.00 |
| 81003 | 0% | 93 | $0.00 | |
| 73080 | 0% | 14 | $0.00 | |
| 80076 | 0% | 13 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 2,377 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,702 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,527 | $0.00 |
| 84132 | 0% | 353 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 434 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 118 | $0.00 |
| 80329 | 0% | 176 | $0.00 | |
| 73502 | 0% | 12 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 73 | $0.00 |
| 82803 | 0% | 46 | $0.00 | |
| 87070 | 0% | 73 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 148 | $0.00 |
| 86140 | 0% | 34 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 29 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 63 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 134 | $0.00 |
| C1769 | Guide wire | 0% | 44 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 163 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 36 | $0.00 |
| 0352U | 0% | 30 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENDRIX, JENIFER (SENIOR NETWORK DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Honorhealth | Phoenix, AZ | $107.15M |
| Honorhealth | Phoenix, AZ | $65.78M |
| Honorhealth | Scottsdale, AZ | $47.05M |
| Honorhealth | Scottsdale, AZ | $23.83M |
| Honorhealth | Scottsdale, AZ | $7.44M |
| Honorhealth | Surprise, AZ | $3.33M |
| Honorhealth | Scottsdale, AZ | $232K |
| Honorhealth | Scottsdale, AZ | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.